Ignite Creation Date:
2025-12-24 @ 10:29 PM
Ignite Modification Date:
2026-02-20 @ 4:14 PM
Study NCT ID:
NCT02485535
Status:
COMPLETED
Last Update Posted:
2021-05-13
First Post:
2015-06-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
Sponsor:
University of Chicago
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2018-02-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-07
Completion Date Type:
ACTUAL
First Submit Date:
2015-06-25
First Submit QC Date:
None
Study First Post Date:
2015-06-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-12
Last Update Post Date:
2021-05-13
Last Update Post Date Type:
ACTUAL